Related Experiment Video
Updated: Aug 11, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Changing boundaries in the treatment of malignant gliomas
A A Brandes1, U Basso, L M Pasetto
1Divisione di Oncologia-Direzione Azienda Ospedale-Universita, Via Giustiniani 2, 35100 Padova, Italy. aabrandes@unipd.it
Abstract:
Malignant gliomas are still among the most lethal and difficult tumors to treat; even the most intensive combinations of radio- and chemotherapy are not curative and yield only a modest impact on survival for most of these patients, as long-term survivors are less than 10%. There is a major need for new chemotherapeutic drugs and alternative therapeutic modalities. This review aims to define the best standard treatment in the common clinical practice and also summarizes the most promising lines of investigational research in the field of neuro-oncology, which will probably offer new and long-awaited valid therapy options for brain tumor patients.
Insights
Malignant gliomas remain difficult to treat, with current therapies offering limited survival benefits. This review explores standard treatments and promising neuro-oncology research for improved brain tumor therapy options.
Area of Science:
- Neuro-oncology
- Oncology
- Cancer Research
Background:
- Malignant gliomas are highly lethal brain tumors with poor prognoses.
- Current standard treatments (radio- and chemotherapy) provide only modest survival improvements.
- Long-term survival rates for malignant glioma patients remain below 10%.
Purpose of the Study:
- To review the current standard treatment for malignant gliomas.
- To summarize promising investigational research in neuro-oncology.
- To identify potential new therapeutic options for brain tumor patients.
Main Methods:
- Literature review of clinical practice guidelines.
- Systematic review of preclinical and clinical research in neuro-oncology.
- Analysis of emerging therapeutic strategies and drug development.
Main Results:
- Standard treatment protocols offer limited efficacy.
- Several novel therapeutic approaches show promise in preclinical and early clinical studies.
- Targeted therapies and immunotherapies are areas of active investigation.
Conclusions:
- There is an urgent need for more effective treatments for malignant gliomas.
- Investigational research in neuro-oncology holds promise for future brain tumor therapies.
- Advancements in drug development and therapeutic modalities are crucial for improving patient outcomes.
